Islet transplantation for type 1 diabetes is limited by a shortage of donor islets and requirement for immunosuppression. We approached this problem by inducing in vivo islet neogenesis in non-obese diabetic (NOD) diabetic mice, a model of autoimmune diabetes. We demonstrate that gene therapy with helper-dependent adenovirus carrying neurogenin3 (Ngn3), an islet lineagedefining transcription factor, and betacellulin (Btc), an islet growth factor, leads to the induction of periportal insulin-positive cell clusters in the liver, which are rapidly destroyed. To specifically accord protection to these 'neo-islets' from cytokine-mediated destruction, we overexpressed suppressor of cytokine signaling 1 (SOCS1) gene, using a rat insulin promoter in combination with Ngn3 and Btc. With this approach, about half of diabetic mice attained euglycemia sustained for over 4 months, regain glucose tolerance and appropriate glucose-stimulated insulin secretion. Histological analysis revealed periportal islet hormone-expressing 'neo-islets' in treated mouse livers. Despite evidence of persistent 'insulitis' with activated T cells, these 'neo-islets' persist to maintain euglycemia. This therapy does not affect diabetogenicity of splenocytes, as they retain the ability to transfer diabetes. This study thus provides a proof-of-concept for engineering in vivo islet neogenesis with targeted resistance to cytokine-mediated destruction to provide a long-term reversal of diabetes in NOD mice.
INTRODUCTION

Type 1 diabetes (T1D) is caused by absolute insulin deficiency resulting from destruction of β cells by autoreactive CD4
+ and CD8 + T cells. This breakdown in tolerance to β-cell self-antigens is thought to be the primary factor involved in disease initiation and progression. These effector T cells initiate β-cell apoptosis and cell death by initiating multiple pathways including those activated by cytokines, fas ligand (CD95L) perforin-granzyme and others. 1, 2 Suppressor of cytokine signaling (SOCS) proteins are characterized by their ability to inhibit the Jak/STAT pathway and thus suppress intracellular signaling of cytokines, especially interferon γ. [3] [4] [5] This regulatory mechanism was shown to robustly prevent β-cell destruction in transgenic mice overexpressing SOCS1 in β cells of non-obese diabetic (NOD) mice and in transplant models. [6] [7] [8] [9] [10] [11] [12] Islet transplantation as a definitive treatment for T1D is severely limited by the availability of donors, and the eventual failure of most transplanted islets because of multiple factors related to immune-mediated destruction, metabolic dysfunction and side effects from immunosuppressive medications and others. [13] [14] [15] [16] We have demonstrated previously in streptozotocin (STZ)-diabetic mice, a non-autoimmune insulin-deficient diabetes mouse model, that helper-dependent adenoviral (HDAd)-mediated gene delivery of neurogenin3 (Ngn3) and betacellulin (Btc) leads to transdetermination of hepatic oval cells into insulin-secreting cells and diabetes reversal. 17 In this report, we show that although this gene therapy leads to induction of insulin-expressing cell clusters in periportal areas of the liver, these 'neo-islets' are quickly destroyed by infiltrating T cells with a return of hyperglycemia. Furthermore, we have developed a novel gene therapy-based strategy that protects the newly formed islets induced by the HDAd-Ngn3-Btc treatment and reverses overt diabetes in a major proportion of T1D NOD mice.
We hypothesized that these Ngn3-Btc-induced 'neo-islets' in the liver could be protected by suppression of cytokine signaling with overexpression of SOCS1. To test this, we used HDAd-Ngn3-Btc gene delivery to induce 'neo-islets' in diabetic NOD mice and combined it with HDAd-RIP-SOCS1 treatment, wherein the rat insulin promoter (Rip)-driven SOCS1 is expressed only in the insulin-producing cells. We demonstrate that, with this approach, a long-term reversal of diabetes is attained in about half of all treated diabetic mice. These mice achieve euglycemia, display normal insulin levels, in vivo glucose-stimulated insulin secretion (GSIS) and display insulin-expressing islet-like clusters in the periportal areas of the liver. Interestingly, these 'neo-islets' despite being surrounded by infiltrating T cells, akin to insulitis seen in the pancreas, continue to express mature islet hormones and islet transcription factors. Thus, this study provides a proof-of-concept that induction of in vivo islet neogenesis and protecting them by modulating immune-mediated β-cell destruction is a viable approach to treating T1D.
RESULTS
Ngn3-Btc gene delivery leads to an evanescent partial amelioration of hyperglycemia in NOD mice
We have previously demonstrated that gene delivery of Ngn3 and Btc, in combination, induces the formation of new islet-like insulinexpressing cell clusters ('neo-islets') in the periportal regions of the liver that effectively reverse STZ-induced insulin-deficient diabetes. 17 We, now, set out to test if this approach is similarly effective in the autoimmune diabetes setting using the NOD mouse model. We followed the NOD mice with weekly blood glucose (0900 to 1000 hours) and body weight measurements from 8 weeks of age. After the onset of diabetes, defined as two consecutive blood glucose measurements 4250 mg dl − 1 , separated by 24 h, we injected the mice with either HDAd carrying Ngn3 (HDAd-Ngn3-5 × 10 11 vp) and Btc (HDAd-Btc-1 × 10 11 vp) or empty vector intravenously, within a 48-h window. Serial blood glucose and body weight determinations revealed that there was only a partial and transient amelioration of the hyperglycemia in the HDAd-Ngn3+Btc mice for the first 1-3 weeks followed by a rapid return to profound hyperglycemia, decreasing body weight and subsequently death within 6-8 weeks (Figures 1a and b) after the onset of diabetes.
Ngn3-Btc gene delivery induces ectopic islet neogenesis in the liver that is rapidly destroyed by autoimmunity The initial response, although transient, correlated to that seen in the non-autoimmune STZ diabetes setting, as previously reported. 17, 18 This led us to reason that the transient response may be the destruction of any induced 'neo-islets' by a resurgent autoimmunity. To test this hypothesis, we killed mice at 4 weeks after treatment and assessed the liver for the presence of insulinexpressing cells. Insulin-expressing cell clusters were seen in the periportal regions of the liver only in the mice treated with HDAdNgn3-Btc, but not in the untreated diabetic mice (Figures 2a and  b) . On further examination, there was a significant infiltration of these insulin-expressing cell clusters with lymphocytes (CD3 + cells in Figures 2c and d) , akin to insulitis seen in the diabetic NOD pancreas (Supplementary Figure 1) .
Ngn3-Btc-RipSOCS1 gene delivery leads to reversal of hyperglycemia Since Ngn3-Btc gene delivery was able to successfully induce insulin-expressing cells in the liver, at least transiently, even in the autoimmune setting of diabetic NOD mice, we reasoned that engineering these neo-islets to resist autoimmunity-driven cytokine-mediated cell death would be an effective approach to accord these 'neo-islets' immune-protection to reverse diabetes. Suppressor of cytokine signaling (SOCS) proteins are induced by cytokines and inhibit the signaling to limit their downstream effects of these cytokines as a negative-feedback loop. 4 However, SOCS1 may have possible undesirable effects when it is expressed in hepatocytes, as it inhibits insulin-induced IRS-1/2 phosphorylation leading to insulin resistance. 19 To circumvent this possible adverse action of SOCS1 in hepatocytes, we transferred the SOCS1 cDNA that is driven by the rat insulin promoter using HDAd, so that SOCS1 expression would be limited to the insulin-expressing neo-islets induced in the liver, protecting them against cytokinemediated cell death, whereas the non-insulin-expressing hepatocytes would not express the SOCS1 transgene and be spared of its possible undesirable action.
We administered HDAd-Ngn3-Btc with either empty HDAd or with HDAd-RipSOCS1 (1 × 10 11 vp) to diabetic NOD mice and monitored their weekly blood glucose and body weight. As shown in Figures 3a and b , there was a significant response, in which about half of diabetic mice (13 out of 28) injected with combination HDAd-Ngn3-Btc-RipSOCS1 demonstrated a complete reversal of hyperglycemia (Figure 3a) , and an increase of body weight (Figure 3b ), in contrast to the two control groups that received only HDAd-Ngn3+Btc (+empty HDAd) or only RipSOCS1. The return to euglycemia was accompanied by a normalization of fasting plasma insulin ( Figure 3c ). Interestingly, even the mice treated with HDAd-Ngn3-Btc-RipSOCS1 that did not have a sustained response and remained hyperglycemic maintained better body weight (non-responders, Figure 3b ) and survived a few weeks longer than the other two control groups not treated with HDAd-RipSOCS1. This was probably secondary to some lowlevel insulin production that was restored, as these mice still had detectable fasting plasma insulin at a level that was higher than the untreated diabetic mice (Figure 3c ). The restoration of euglycemia and plasma insulin in the mice treated with HDAdNgn3-Btc-RipSOCS1 was not due to insulin secretion from the pancreas as there were no residual islets detectable in the pancreas of these mice (Supplementary Figure 1) . There was no evidence of hepatotoxicity as both the morphology of hepatocytes and serum aspartate aminotransferase levels were normal in the treated mice (Supplementary Figure 2) .
Ngn3-Btc-RipSOCS1 gene delivery leads to reversal of glucose intolerance and restoration of in vivo GSIS As GSIS is the hallmark of a mature and fully functional β cell, we assessed glucose tolerance and GSIS during a glucose tolerance test on the treated mice. The treated mice had a normal glucose tolerance that was accompanied by a normal in vivo GSIS as measured by plasma insulin during the glucose tolerance test (Figures 4a and b) . This was in contrast to untreated diabetic mice that had no significant increase in their plasma insulin during the glucose tolerance test. This normalization of glucose intolerance seen in diabetic NOD mice strongly indicated that there were normally functioning insulin-secreting β cells that were induced by treatment with HDAd-Ngn3-Btc-RipSOCS1.
Ngn3-Btc-SOCS1 gene delivery leads to neo-islet formation in the periportal areas of the liver Our previous work in non-autoimmune STZ diabetes model indicated that HDAd-Ngn3-Btc-induced neo-islets from oval cells in the periportal areas of the liver without any induction of islet regeneration in the pancreas. 17 We, therefore, tested if indeed there were insulin-positive 'neo-islets' in the portal triads of the treated diabetic NOD mice. A similar induction of A6-positive oval cell clusters are prominently seen in all Ngn3-Btc-treated NOD mice (Supplementary Figure 3) . As shown in Figure 5a , there were insulin-producing clusters of cells in these periportal areas in the mice that received Ngn3-Btc-RipSOCS1 but not in untreated diabetic mice and only rarely in the mice that received Ngn-Btc but not RipSOCS1. This strongly suggested that the HDAd-Ngn3-Btc gene delivery induced insulin-positive cells in the liver and that RipSOCS1 was instrumental in the reversal of hyperglycemia with restoration of plasma insulin by allowing the persistence of Ngn3-Btc-SOCS1 gene therapy reverses NOD diabetesthese 'neo-islets'. In addition, these neo-islets also express other islet hormones, such as glucagon, somatostatin and pancreatic polypeptide (Figures 5b and 5f ) along with islet-specific transcription factors in the liver, including Nkx6.1 and Pdx1 (Figures 5d and  f) . These cells persistently expressed high levels of Ngn3 (Supplementary Figure 4) . Interestingly, the mice that had received HDAd-Btc-RipSOCS1 but did not have a sustained reversal of hyperglycemia (non-responders) still exhibited the other islet hormone-expressing cells (data not shown) surrounded by 'insulitis' in the periportal regions. This suggested that even in the non-responders the 'neo-islets' were induced, but unlike in the responder mice, in these mice the insulin-expressing cells were likely destroyed by the infiltrating lymphocytes.
Ngn3-Btc-SOCS1 gene delivery leads to persistence of ectopic neo-islets in the liver despite surrounding insulitis Our strategy of induced overexpression of SOCS1 only in the insulin-positive cells in the liver would be expected to impair the intracellular cytokine signaling in these cells but not affect the activation of and migration of lymphocytes to the periportal areas harboring the 'neo-islets'. Hence, not surprisingly, there is a significant collection of lymphocytes, as detected by their CD3-positive expression ( Figure 6 ) in the periportal areas, suggestive of 'insulitis', of all mice that were treated with Ngn3-Btc, whether or not they received RipSOCS1 in addition. Furthermore, this was also accompanied by a significant expression tumor necrosis factor-α, suggesting activation of these lymphocytes invading the periportal areas of the liver ( Figure 6 ). These results demonstrate that the NOD mice did mount an autoimmune response against the induced 'neo-islets' in the liver, but were unable to destroy the 'neo-islets' that received Ngn3-Btc-RipSOCS1, as indicated by a persistence of the insulin-positive cell clusters.
Ngn3-Btc-SOCS1 does not lead to peripheral immunosuppression This approach to protect the 'neo-islets' from immune-mediated cell death by limiting the transgene expression of SOCS1 to the neo-islets in the liver would not be expected to lead to peripheral immunosuppression or immune tolerance. However, to definitively test this we performed an adoptive transfer of splenic lymphocytes harvested from HDAd-Ngn3-Btc-RipSOCS1-treated mice that became euglycemic and HDAd-Ngn3-Btc-treated mice that remained hyperglycemic, into 6-week-old female NOD-Scid mice. On follow-up of weekly blood glucose, there was no difference in the development of diabetes between the two groups ( Figure 7 ). This indicated that the splenocytes from the Ngn3-Btc-RipSOCS1-treated mice were equally diabetogenic as those mice that were hyperglycemic and had not received RipSOCS1. In other words, RipSOCS1 did not induce any peripheral immunosuppression and this was not the cause of the observed response of diabetes reversal. In summary, these results demonstrate that HDAd-Ngn3-Btc could be used to induce 'neo-islets' in the liver of diabetic NOD mice and that these 'neo-islets' could be protected from autoimmune destruction by overexpression of SOCS1 without peripheral immunosuppression.
DISCUSSION
With increasing evidence that current immunosuppressive protocols for islet transplantation have fallen short of enabling a longterm cure of T1D, 16, 20, 21 the need for alternate therapeutic strategies becomes more urgent. To circumvent the need for donors and associated immunosuppression for alloimmunity, we have adopted a gene therapy approach to induce islet neogenesis in vivo. We have previously shown that Ngn3-Btc gene therapy induces hepatic oval cells to transdetermine into insulin and other islet hormone-expressing 'neo-islets' that reverse insulin-deficient STZ diabetes. 17 In this study, we tested this approach in an autoimmune setting to determine whether these 'neo-islets' will trigger autoimmunity and if so, could these be engineered to acquire target cell-specific resistance to immune destruction to induce long-term reversal of diabetes in NOD mice.
In this study, we first provide evidence that gene delivery of Ngn3 in combination with Btc is sufficient to induce 'neo-islets' that express insulin, in the liver of diabetic NOD mice, but these are targeted by autoreactive T cells culminating in their destruction. This implies that the 'neo-islets' induced by Ngn3-Btc appear to behave, immunologically, in a very similar manner as mature native or transplanted islets in that they trigger an identical autoimmune response that targets pancreatic islets. This, of in itself, is very different from earlier gene therapy studies that had attempted in a reversal of diabetes in NOD mice by either producing insulin in the hepatocytes (NOD-PEPCK-Ins Tg) 22 or converting the hepatocytes into insulin-producing cells using PDX1 gene therapy, 23 as in both of these studies the insulinproducing cells behave differently as compared with native mature β cells and appear not to be targeted indicating that these were not recognized as β cells by the immune system.
We then demonstrate that an overexpression of SOCS1, a suppressor of cytokine signaling, in these neo-islets is sufficient to accord protection from autoimmune destruction in about half of diabetic mice and render them euglycemic for an extended period Ngn3-Btc-SOCS1 gene therapy reverses NOD diabetes R Li et al of time. As expected, the SOCS1 overexpression does not prevent 'insulitis' in the liver or the pancreas. However, the 'neo-islets' in the liver are protected from destruction as evidenced by their persistence despite the insulitis. This is consistent with previous reports indicating persistent insulitis in the pancreas of NODtransgenic mice expressing SOCS1 in the β cells. 8, 24 It has also been suggested that in addition to the direct effects of cytokine signaling, SOCS1 may protect β cells by affecting target cell recognition. 24 However, in this study, the overexpression of SOCS1 did not induce a suppression of the diabetogenicity of peripheral T cells, as splenocytes from these mice induce diabetes in adoptive transfer experiments. Interestingly, these results are in contrast to those from Ad-Rip-PDX1 gene therapy-treated NOD mice, wherein the authors found that the mice treated with Ad-Rip-PDX1 developed immunotolerance and had reduced diabetogenicity on adoptive transfer experiments, although the mechanisms remain unexplained. 23 Furthermore, it has been reported that the lymphocytes infiltrating the islets from NODSOCS1Tg mice did have a reduced diabetogenicity and this was thought to be resulting from SOCS1 in the target β-cell preventing apoptosis-driven antigen release and thus reducing the presentation of antigens and subsequent activation of more T cells. 8 It remains to be determined whether this was also the case with the T cells surrounding the 'neo-islets' in the liver.
We achieved a reversal of hyperglycemia in about half (13/28 mice) of the treated mice with the overexpression of SOCS1 in the 'neo-islets'. The remaining mice did display 'neo-islets' with other hormone-expressing cells but appear to have lost only the insulinexpressing cells leading to their lack of sustained reversal of hyperglycemia. The lack of sustained response likely results from destruction of the induced insulin-expressing cells by immune mechanisms that are independent of SOCS1-mediated inhibition or by those that can overcome it. As there are multiple pathways that mediate the ultimate destruction of β cells in autoimmune diabetes in NOD mice, 1 it is not entirely unexpected that there was a significant fraction of diabetic mice that did not achieve euglycemia by induced overexpression of SOCS1. This is in keeping with the data from SOCS1 transgenic NOD mice wherein a protection was accorded to 30-80% of mice depending on the transgenic line. 6, 9 Interestingly, most of the mice that did not have Values (mean ± s.e.m.) are expressed after normalization relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and eukaryotic translation elongation factor 1 gamma (eEF1γ). PV, portal vein. Scale bars represent 50 μm in all except for the higher magnification insets in a-c, wherein the scale bars represent 10 μm. *P ⩽ 0.05 as compared with controls (non-diabetic and Ngn3-Btc).
Ngn3-Btc-SOCS1 gene therapy reverses NOD diabetessustained response were mice that became diabetic at a much earlier age than the responders. This could imply that the mice that became diabetic at an earlier age had a more aggressive autoimmunity and hence could not be protected from by the overexpression of SOCS1. This interesting observation opens the window to future studies to address if there are differences in mechanisms that determine the aggressive nature of the diabetes that may require unique targeting. In summary, this study demonstrates that using Ngn3-Btc to induce 'neo-islets' in the liver of NOD mice and then subsequently accord target cell protection from cytokine-mediated cell death by overexpressing SOCS1 is a viable approach to reverse autoimmune diabetes in NOD mice. SOCS1-independent pathways may also need to be targeted to allow a more universal response to the Ngn3-Btc therapy in the future.
MATERIALS AND METHODS Animals
All animal protocols were approved by the IACUC at Baylor College of Medicine. NOD female mice were purchased from Jackson Labs (Bar Harbor, ME, USA) at 8 weeks of age and followed weekly with non-fasting blood glucose (One touch glucometer, LifeScan, Milpitas, CA, USA) and body weight measurements between 0900 and 1000 hours on regular chow (2020 × Teklad). If the blood glucose was greater than 250 mg dl − 1 , it was retested the following day. Diabetes was defined as two consecutive blood glucose measurements 4250 mg dl − 1 . Diabetic mice were treated with HDAd vectors by tail vein injection within 48 h after the diagnosis of diabetes. Glucose tolerance testing was performed, as described before, 17 at 4 weeks after treatment in 6 h fasted mice with an intra-peritoneal injection of 1.5 gm kg − 1 body weight of D-glucose. Insulin was assayed using the Mercodia Ultrasensitive ELISA kits (Winston Salem, NC, USA).
Vectors
Construction of the mouse Ngn3, Btc viruses has been described before. HDAd-RIP-SOCS1 was also constructed similarly. In brief, mouse SOCS1 cDNA were cloned from the spleen by reverse transcription-PCR and the fully sequenced cDNA were then sub-cloned into pLPBL1 shuttle plasmid with a rat insulin promoter and rabbit β-globin polyadenylation signal. We used p-delta28 plasmids as backbone for the HDAds and these were amplified as described previously. 25 Diabetic mice were administered a single intravenous injection of HDAd vectors via tail vein. To exclude any non-specific effect related to vector dose, the total vector dose was maintained at 7 
Gene expression
Liver and pancreas were removed at stated time points from anesthetized mice, snap frozen in liquid nitrogen and stored at − 80°C. They were homogenized in Trizol Reagent (Invitrogen, Grand Island, NY, USA) and total RNA extracted as per the manufacturer's instructions. This RNA was then subjected to an on-column purification and DNaseI digestion (RNeasy mini, Qiagen, Valencia, CA, USA) to remove any genomic DNA contamination. The eluted RNA was quantitated and stored at − 80°C. Reverse transcription was performed by using 20 μg of RNA with Superscript reverse transcription III cDNA synthesis kit (Invitrogen). We performed quantitative real-time PCR using SYBR Green reagent (Bio-Rad, Hercules, CA, USA). The Ct values were obtained after normalizing to the non-reactive ROX dye, which served as a reference control. Using the delta-delta-Ct method, after normalizing to housekeeping genes (glyceraldehyde 3-phosphate dehydrogenase), we quantified various transcripts using appropriate primers (Supplementary Table 1 ) and analyzed melting curves to confirm accurate readings.
Immunostaining
Immunostaning was performed as described before. 17 Primary antibodies used were insulin (1:100 guinea pig polyclonal, Abcam, Cambridge, MA, USA), Glucagon ( 
Adoptive transfer
Splenocytes were isolated by collagenase digestion and 2 × 10 6 cells in 250 μl serum-free media were injected IP into 6-week-old female NOD-Scid mice (purchased from Jackson Laboratories, Bar Harbor, ME, USA). Weekly blood glucose was measured in these NOD-Scid mice to determine the diabetes transfer rate.
Statistical methods
All statistical testing was performed either by two-tailed student's t-testing, assuming unequal variance for two groups, or by analysis of variance for multiple group testing (with Tukeys for post-hoc analysis). P ⩽ 0.05 considered significant between the groups. For adoptive transfer experiment, Kaplan-Meier survival analysis using log-rank test was used to determine significant with Po0.05 being considered significant. Statement regarding sample sizes: Sample sizes were chosen based on previous pilot studies to obtain reproducible results in physiological testing. Mice were chosen for different treatments randomly but to ensure that the final groups were similar at baseline before treatment. Where possible for analysis, the analysis was blinded during data collection.
